Aspiriant LLC Cuts Stake in Johnson & Johnson (NYSE:JNJ)

Aspiriant LLC decreased its holdings in Johnson & Johnson (NYSE:JNJ) by 6.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 20,992 shares of the company’s stock after selling 1,368 shares during the period. Aspiriant LLC’s holdings in Johnson & Johnson were worth $3,481,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also modified their holdings of the stock. Tallon Kerry Patrick purchased a new stake in Johnson & Johnson during the 4th quarter worth about $290,000. Capital & Planning LLC grew its position in shares of Johnson & Johnson by 13.6% during the fourth quarter. Capital & Planning LLC now owns 1,528 shares of the company’s stock worth $221,000 after buying an additional 183 shares in the last quarter. Brighton Jones LLC increased its stake in shares of Johnson & Johnson by 13.9% during the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock worth $7,502,000 after buying an additional 6,332 shares during the period. Union Bancaire Privee UBP SA acquired a new stake in Johnson & Johnson in the fourth quarter valued at approximately $85,886,000. Finally, Strategic Financial Concepts LLC lifted its stake in Johnson & Johnson by 57.9% in the fourth quarter. Strategic Financial Concepts LLC now owns 3,467 shares of the company’s stock worth $501,000 after acquiring an additional 1,271 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Down 1.1%

Shares of Johnson & Johnson stock opened at $150.77 on Friday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26. The company has a market capitalization of $362.76 billion, a P/E ratio of 16.77, a PEG ratio of 2.28 and a beta of 0.42. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99. The company’s fifty day moving average is $154.11 and its two-hundred day moving average is $153.64.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.59 by $0.18. The firm had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. Analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were issued a $1.30 dividend. The ex-dividend date was Tuesday, May 27th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.45%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.24. Johnson & Johnson’s payout ratio is presently 57.84%.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on JNJ. Royal Bank Of Canada restated an “outperform” rating and issued a $181.00 price objective on shares of Johnson & Johnson in a report on Thursday, June 5th. Benchmark upgraded Johnson & Johnson to a “strong-buy” rating in a research note on Thursday, April 24th. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Guggenheim restated a “neutral” rating on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. Finally, Leerink Partnrs lowered shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 13th. Eleven research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $170.88.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.